Can Biotechs Ever Be Free of Big Pharma? Inside the Thought Experiment That’s Reshaping R&D

I’ve been asking myself a question that’s almost heretical in this industry.

Could biotechs ever be free of Big Pharma?

It’s not a cynical question. It’s a practical one — and one that feels increasingly relevant in a world where a five-person team can run an entire clinical program with AI-powered analytics, a virtual CRO, and digital site networks.

Everywhere I look, the boundaries are dissolving. Biotechs can license molecules from universities, run decentralized trials, generate regulatory-ready datasets, and even commercialize rare disease drugs with digital-first engagement teams.

So why not complete the arc? Why not a world where a biotech never sells, never merges, never hands its life’s work to a multinational machine?

That’s the question I brought to Chris Moore, President of Veeva Europe — and the conversation made me realize something unsettling. Independence isn’t just a matter of technology or will. It’s a matter of ecosystem physics.

The Thought Experiment: The Biotech That Needs No One

Imagine a future biotech — let’s call it VibroGen.

VibroGen starts the way many do: a university spinout, three founders, one molecule. But instead of chasing Series C funding or a Big Pharma exit, they decide to stay small.

AI-powered platforms handle the work of hundreds of analysts.

• Discovery: algorithms model binding affinities and toxicity profiles in silico.
• Trial design: predictive engines simulate patient cohorts, diversity targets, and outcomes.
• Clinical operations: automated site management tools, wearables, and digital endpoints cut trial timelines in half.
• Regulatory: data lakes structured to FDA and EMA standards auto-generate eCTDs.
• Commercialization: a digital engagement engine maps every clinician, payer, and patient advocacy group — all without a single sales rep.

In this world, VibroGen runs on data, not hierarchy.

The entire company might have 50 people — all specialized, all augmented by AI. They don’t need the capital overhead of manufacturing plants because biologics are produced on demand via modular microfactories. Distribution is handled through decentralized partnerships.

In theory, this biotech could go all the way.

In practice, it would still collide with reality.

The Invisible Hand of Infrastructure

That collision starts with one simple truth: scale is expensive even when technology is efficient.

Even if AI halves development timelines, a late-stage global trial still costs tens — if not hundreds — of millions of dollars. Regulatory filings require harmonized, auditable data pipelines across continents. Market access depends on years of payer negotiations, real-world evidence, and post-market surveillance.

These aren’t inefficiencies; they’re the price of global trust.

Chris Moore put it bluntly: “The funding doesn’t go away. The underlying cost of developing a drug — if anything — has gone up.”

And it’s not just money. It’s expertise.

Even the most agile biotech can’t replicate the web of relationships, logistics, and compliance systems that Big Pharma has refined over decades. You can’t AI your way out of trust networks — those invisible relationships between regulators, payers, and providers that ultimately decide whether a new therapy is adopted.

So even if VibroGen builds the perfect digital twin of its operations, it still needs access to the ecosystem — the infrastructure that converts discovery into delivery.

The Capital Equation

There’s also the gravitational pull of capital markets.

Drug development isn’t linear; it’s probabilistic. A biotech may run ten programs and see one through to success. For that one, every dollar invested in the other nine must be recouped. Big Pharma’s balance sheets exist to absorb that risk.

Could AI make development so precise that risk becomes negligible? Perhaps — but not yet. As Moore pointed out, “The easy diseases have been solved. We’re now in the really hard stuff — oncology, neurodegeneration, rare diseases. No one company is going to cure cancer. It’s going to take whole ecosystems to do it.”

The more complex the science becomes, the larger the network required to sustain it. Independence, paradoxically, demands deeper interdependence.

The Data Barrier

Then there’s data — the substrate of everything.

AI can make a company hyper-efficient only if its data is pristine, structured, and unified. But most biotechs don’t own the kind of longitudinal datasets that make AI powerful. Their data ends at the trial boundary.

Big Pharma, by contrast, operates across thousands of studies, markets, and patient registries. That cross-domain visibility is what makes their insights predictive, not just descriptive.

Moore illustrated this through a simple example: “If you describe a doctor one way in France and another in Germany, your AI can’t scale. The sexy part isn’t the model; it’s harmonizing the definitions underneath.”

Until biotechs have access to shared, harmonized data ecosystems, their independence will remain partial — technically possible, but strategically fragile.

The Cultural Constraint

Even if the technology and funding aligned, there’s still a cultural problem.

Pharma is not just regulated; it’s risk-averse by design. Every decision carries patient, legal, and financial implications. That conservatism often clashes with the startup ethos of rapid iteration.

For biotechs to be truly independent, they’d need not only tools, but mindset infrastructure — a culture that marries the rigor of regulatory compliance with the agility of innovation.

That means digital-first validation frameworks, algorithmic audit trails, and real-time compliance monitors that can stand up to FDA scrutiny without manual oversight.

The technology exists in pieces. The mindset doesn’t.

As Moore noted, “The hardest thing is getting people to stop doing what they’ve always done. You can give them new systems, but unless they change how they work, it just adds more layers.”

The Only Path to True Autonomy

So, is biotech independence impossible? Not exactly. It’s just conditional.

A truly autonomous biotech would need to reinvent the industry’s infrastructure from the ground up — creating an open, federated ecosystem where trust, data, and validation no longer depend on corporate scale.

Here’s what that might look like:

1. Open Clinical Data Commons A global framework where anonymized patient data, trial outcomes, and safety signals flow freely between verified nodes — regulated like a public utility, not a private asset.
2. Modular Manufacturing Networks AI-managed bioreactors distributed across continents, certified to shared GMP standards. No single entity owns the network; all contribute capacity.
3. Automated Regulatory Intelligence Digital regulatory agents trained on real-time FDA and EMA precedent, capable of generating context-aware submissions that adapt to new guidances autonomously.
4. Smart Contracts for Clinical Partnerships Blockchain-backed agreements that automate milestone payments, data sharing, and IP rights — replacing human legal bottlenecks with executable trust.
5. Federated Capital Pools Tokenized funding platforms allowing multiple micro-investors — from governments to patients — to back specific molecules, spreading risk beyond traditional venture structures.

In that world, Big Pharma’s traditional role — funding, scaling, and legitimizing — could dissolve into the network itself. Power would shift from conglomerates to protocols.

It’s a radical thought, but not a fantasy. It’s what the intersection of AI, Web3, and regulatory digitization is quietly building toward.

Moore’s Counterpoint: The Human Constant

When I outlined this vision to Chris Moore, he smiled.

“It’s a compelling future,” he said, “but even then, humans don’t go away. This is still a compliant industry. We’ll always need skilled professionals. AI can make them 30% more efficient — not redundant.”

That’s the key tension: autonomy of systems vs. dependence on expertise.

The more sophisticated the technology becomes, the more valuable judgment becomes — the scientist interpreting AI-generated data, the clinician validating digital endpoints, the ethicist questioning algorithmic bias.

Even in a world of perfect automation, human oversight remains the last mile of trust.

So, Could Biotech Be Free?

Maybe — but not in the way we first imagined.

Freedom won’t mean separation from Big Pharma; it will mean freedom from its limitations — the bureaucracy, the silos, the slow feedback loops.

Technology will make biotechs capable of end-to-end innovation. But those that thrive won’t reject the ecosystem. They’ll redefine it — forming digital alliances, shared data infrastructures, and hybrid operational models that look less like corporate hierarchies and more like neural networks.

Independence will come not through isolation, but through mutual intelligence.

In that sense, the future of biotech isn’t David vs. Goliath. It’s David learning to think like a network — small, adaptive, and infinitely connected.

And when that happens, maybe we’ll stop talking about “Big” and “Small” Pharma altogether.

We’ll just call it one intelligent biopharma system — where data, people, and machines collaborate without borders.

Because in the end, freedom won’t be about who owns the molecule.

It’ll be about who owns the moment of insight that changes medicine forever.